Coronary disease & ACS

Nonculprit Lesion Complexity and Timing of Complete Revascularization in Patients Presenting With Acute Coronary Syndrome and Multivessel Disease: Insights From the BIOVASC Trial

Circ Cardiovasc IntervPublished exploratory post hoc analysis

Primary result · Composite of all-cause mortality, myocardial infarction, unplanned ischemia-driven revascularization, or cerebrovascular eventsResult — go to the resultAdjusted hazard ratio 1.49 95% CI 1.11–2.02

Authors' conclusion

In patients with acute coronary syndrome and multivessel disease, patients with complex NCL experienced worse clinical outcomes at 2-year follow-up, driven by higher rates of myocardial infarction. However, no statistically significant interaction was observed between NCL complexity and the effect of immediate complete revascularization versus staged complete revascularization.

Study context

Population
Patients with acute coronary syndrome and multivessel diseaseenrolled in the BIOVASC trial, 550 (36.1%) had a complex nonculprit coronary lesions (NCL)
Participants
1,525 patients
Comparison
Immediate complete revascularization and staged complete revascularization in patients with complex NCL; complex vs noncomplex NCLs
  • Complex NCLn = 550
Primary endpoint
Composite of:
  • All-cause mortality
  • Myocardial infarction
  • Unplanned ischemia-driven revascularization
  • Cerebrovascular events
Follow-up
2-year follow-up
Methodological detailsBIOVASC trial randomized patients
  • BIOVASC trial randomized patients

Primary result

As reported in the abstract

Composite of all-cause mortality, myocardial infarction, unplanned ischemia-driven revascularization, or cerebrovascular…

Adjusted hazard ratio

1.49

95% CI 1.11–2.02

P = 0.01

Complex NCLvs noncomplex NCL
adjusted hazard ratio 1.49 (95% CI 1.11–2.02); P = 0.01

Further findings

Cumulative incidence

OutcomeImmediate complete revascularizationStaged complete revascularizationEstimateP value
Spontaneous myocardial infarctionComplex NCLvs noncomplex NCLadjusted hazard ratio 1.86 (95% CI 1.12–3.09)P = 0.02
Primary end point in patients with complex NCLImmediate complete revascularizationvs staged complete revascularization15.7%17.5%hazard ratio 0.86 (95% CI 0.57–1.31)P = 0.49
  • Primary end point in patients with complex NCL: P for interaction=0.40 (complex NCL × revascularization strategy)

Original publication

Nonculprit Lesion Complexity and Timing of Complete Revascularization in Patients Presenting With Acute Coronary Syndrome and Multivessel Disease: Insights From the BIOVASC Trial. Circ Cardiovasc Interv. Published 13 November 2026. doi:10.1161/circinterventions.126.017520

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.